GlaxoSmithKline said it has received and rejected three bids from consumer products giant Unilever to acquire its consumer drugs arm. The latest offer, worth £50 billion...

In the VAT 0002 extension trial investigating the safety and immunogenicity of the protein-based recombinant adjuvanted Covid-19 vaccine they are partly developing as a...

Britain’s largest drugmaker, GlaxoSmithKline (GSK) has landed a major coup, luring Pfizer’s vaccines R&D chief away, as it tries to regain its position in the top tier of...

The World Health Organization (WHO) has recommended administering GlaxoSmithKline’s 33-year-old malaria vaccine to children across Africa in the hope of stalling the...

A year ago unthinkable, the market for mRNA-based Covid-19 vaccines appears to be headed for saturation, even though, or perhaps because, there now seem to be more...

Activist hedge fund Bluebell Capital Partners has joined activist investor Elliott Management, GlaxoSmithKline’s long-time nemesis, in trying to force a leadership...

CV2Cov, the next-generation Covid-19 vaccine under development by German biotech CureVac and UK drugs giant GSK, outperformed CureVac’s first-generation Covid shot in...

GlaxoSmithKline (GSK), the UK’s largest drugmaker, plans to establish a new life sciences campus within its R&D site at Stevenage, England. The company said it is...